Tetsuya Mitsudomi

Research interests

Publications

• Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2023 · https://doi.org/10.1056/nejmoa2304875

• Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial

  The Lancet · 2022 · https://doi.org/10.1016/s0140-6736(21)02333-3

• Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer

  Journal of Thoracic Oncology · 2021 · 10.1016/j.jtho.2021.06.017

• IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy

  Journal of Thoracic Oncology · 2020 · 10.1016/j.jtho.2020.01.005

• Comparison of pulmonary segmentectomy and lobectomy: Safety results of a randomized trial

  Journal of Thoracic and Cardiovascular Surgery · 2019 · https://doi.org/10.1016/j.jtcvs.2019.03.090

• Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial

  The Lancet · 2017 · https://doi.org/10.1016/s0140-6736(17)30565-2

• Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)30508-3

• Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy

  Cancer Science · 2016 · https://doi.org/10.1111/cas.12996

• Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)00099-1

• Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia

  Nature Genetics · 2012 · https://doi.org/10.1038/ng.2456

• International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

  Journal of Thoracic Oncology · 2011 · https://doi.org/10.1097/jto.0b013e318206a221

• A Prospective Radiological Study of Thin-Section Computed Tomography to Predict Pathological Noninvasiveness in Peripheral Clinical IA Lung Cancer (Japan Clinical Oncology Group 0201)

  Journal of Thoracic Oncology · 2011 · https://doi.org/10.1097/jto.0b013e31821038ab

• EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors

  New England Journal of Medicine · 2010 · https://doi.org/10.1056/nejmoa1007478

• Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

  The Lancet Oncology · 2009 · https://doi.org/10.1016/s1470-2045(09)70364-x

• Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer

  FEBS Journal · 2009 · https://doi.org/10.1111/j.1742-4658.2009.07448.x

• Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutations

  Cancer Research · 2008 · https://doi.org/10.1158/0008-5472.can-08-1643

• MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

  Science · 2007 · https://doi.org/10.1126/science.1141478

• Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer

  Cancer Science · 2007 · https://doi.org/10.1111/j.1349-7006.2007.00607.x

• Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib

  Clinical Cancer Research · 2006 · https://doi.org/10.1158/1078-0432.ccr-06-0714

• Reduced expression of Dicer associated with poor prognosis in lung cancer patients

  Cancer Science · 2005 · https://doi.org/10.1111/j.1349-7006.2005.00015.x

• Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Non–Small-Cell Lung Cancer With Postoperative Recurrence

  Journal of Clinical Oncology · 2005 · https://doi.org/10.1200/jco.2005.00.992

• Reduced Expression of the let-7 MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival

  Cancer Research · 2004 · https://doi.org/10.1158/0008-5472.can-04-0637

• Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer

  Cancer Research · 2004 · https://doi.org/10.1158/0008-5472.can-04-2818

• Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas.

  PubMed · 1998

• P53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features

  Lung Cancer · 1992 · https://doi.org/10.1016/0169-5002(92)90040-q

• Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group.

  PubMed · 1990

Current projects

No projects listed.